Breaking News

Friday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
HMS Holdings added as a positive Fresh Pick at Baird » 08:33
05/22/20
05/22
08:33
05/22/20
08:33
HMSY

HMS Holdings

$27.01 /

-0.07 (-0.26%)

Baird analyst Matthew…

Baird analyst Matthew Gillmor added HMS Holdings as a positive Fresh Pick following recent meetings with management. He said State budget pressures and and a potential sharp increase in Medicaid enrollment could drive upside to his estimates. He also sees its current valuation expanding as 2021 growth drivers come into better focus. Gillmor reiterated his Outperform rating and $40 price target on HMS Holdings shares.

ShowHide Related Items >><<
HMSY HMS Holdings
$27.01 /

-0.07 (-0.26%)

HMSY HMS Holdings
$27.01 /

-0.07 (-0.26%)

04/20/20 RBC Capital
HMS Holdings initiated with a Sector Perform at RBC Capital
04/13/20 SVB Leerink
HMS Holdings initiated with an Outperform at SVB Leerink
02/24/20 Canaccord
HMS Holdings price target lowered to $38 from $46 at Canaccord
01/08/20 Credit Suisse
HMS Holdings reinstated with an Outperform at Credit Suisse
HMSY HMS Holdings
$27.01 /

-0.07 (-0.26%)

Over a week ago
Earnings
HMS Holdings lowers FY20 revenue view to $690M-$705M from $705M-$715M » 06:11
05/08/20
05/08
06:11
05/08/20
06:11
HMSY

HMS Holdings

$27.29 /

-1.11 (-3.91%)

Consensus for FY20…

Consensus for FY20 revenue is $704.18M. Lowers FY20 adjusted EBITDA view to $177M-$187M from $185M-$192M.

ShowHide Related Items >><<
HMSY HMS Holdings
$27.29 /

-1.11 (-3.91%)

04/20/20 RBC Capital
HMS Holdings initiated with a Sector Perform at RBC Capital
04/13/20 SVB Leerink
HMS Holdings initiated with an Outperform at SVB Leerink
02/24/20 Canaccord
HMS Holdings price target lowered to $38 from $46 at Canaccord
01/08/20 Credit Suisse
HMS Holdings reinstated with an Outperform at Credit Suisse
Earnings
HMS Holdings reports Q1 adjusted EPS 32c, consensus 25c » 06:09
05/08/20
05/08
06:09
05/08/20
06:09
HMSY

HMS Holdings

$27.29 /

-1.11 (-3.91%)

Reports Q1 revenue…

Reports Q1 revenue $171.4M, consensus $162.32M. "HMS delivered solid top-line growth with Q1 revenue increasing 15.9% compared with the same period last year, driven by strong organic growth of 8.5% plus a full quarter of the Accent business acquired at the end of 2019," said CEO Bill Lucia. "Net income declined 35.4% year-over year in the quarter, due primarily to Accent-related integration costs this year and discrete tax benefits in 1Q19. Adjusted EBITDA increased 15.0% and cash and cash equivalents topped $148M at quarter end. With healthy cash flows and low leverage, HMS continues to be well positioned to invest in our talent, technology and product development to support our business growth and clients' needs".

ShowHide Related Items >><<
HMSY HMS Holdings
$27.29 /

-1.11 (-3.91%)

04/20/20 RBC Capital
HMS Holdings initiated with a Sector Perform at RBC Capital
04/13/20 SVB Leerink
HMS Holdings initiated with an Outperform at SVB Leerink
02/24/20 Canaccord
HMS Holdings price target lowered to $38 from $46 at Canaccord
01/08/20 Credit Suisse
HMS Holdings reinstated with an Outperform at Credit Suisse
Over a month ago
Initiation
HMS Holdings initiated with a Sector Perform at RBC Capital » 16:26
04/20/20
04/20
16:26
04/20/20
16:26
HMSY

HMS Holdings

$28.06 /

+0.22 (+0.79%)

RBC Capital analyst Sean…

RBC Capital analyst Sean Dodge initiated coverage of HMS Holdings with a Sector Perform rating and $27 price target. The analyst wants to see evidence the company's recent re-tooling of its sales force is building a revenue-generating pipeline before getting more constructive on the shares.

ShowHide Related Items >><<
HMSY HMS Holdings
$28.06 /

+0.22 (+0.79%)

04/13/20 SVB Leerink
HMS Holdings initiated with an Outperform at SVB Leerink
02/24/20 Canaccord
HMS Holdings price target lowered to $38 from $46 at Canaccord
01/08/20 Credit Suisse
HMS Holdings reinstated with an Outperform at Credit Suisse
11/22/19 Guggenheim
Guggenheim upgrades HMS Holdings to Buy on 'compelling' risk/reward
Initiation
HMS Holdings initiated with an Outperform at SVB Leerink » 08:49
04/13/20
04/13
08:49
04/13/20
08:49
HMSY

HMS Holdings

$26.74 /

+1.18 (+4.62%)

SVB Leerink analyst…

SVB Leerink analyst Stephanie Davis Demko initiated coverage of HMS Holdings with an Outperform rating and $31 price target. The analyst believes 2020 will be a battleground year for the healthcare landscape on both post-COVID-19 recession fears and headline risk surrounding the election. Given the uncertain macro backdrop, she prefers names benefiting from secular growth trends that will overshadow market volatility, with a high level of revenue visibility and potential for upward estimate revisions in fiscal year 2020, and closest to the consumer, where Davis Demko sees the strongest near-term demand.

ShowHide Related Items >><<
HMSY HMS Holdings
$26.74 /

+1.18 (+4.62%)

02/24/20 Canaccord
HMS Holdings price target lowered to $38 from $46 at Canaccord
01/08/20 Credit Suisse
HMS Holdings reinstated with an Outperform at Credit Suisse
11/22/19 Guggenheim
Guggenheim upgrades HMS Holdings to Buy on 'compelling' risk/reward
11/22/19 Guggenheim
HMS Holdings upgraded to Buy from Neutral at Guggenheim
Over a quarter ago
Recommendations
HMS Holdings price target lowered to $38 from $46 at Canaccord » 08:34
02/24/20
02/24
08:34
02/24/20
08:34
HMSY

HMS Holdings

$24.23 /

-3.24 (-11.79%)

Canaccord analyst Richard…

Canaccord analyst Richard Close lowered his price target on HMS Holdings to $38 from $46 as the company missed both its Q4 and 2020 forecasts. The analyst lowered his estimates as well based on the new guidance but he is keeping a favorable outlook based on it recent Accent acquisition and its cross-selling opportunity, continued PI strength, and positive population management which keeps it better positioned for growth than ever before. Close reiterated his Buy rating on HMS Holdings shares.

ShowHide Related Items >><<
HMSY HMS Holdings
$24.23 /

-3.24 (-11.79%)

01/08/20 Credit Suisse
HMS Holdings reinstated with an Outperform at Credit Suisse
11/22/19 Guggenheim
Guggenheim upgrades HMS Holdings to Buy on 'compelling' risk/reward
11/22/19 Guggenheim
HMS Holdings upgraded to Buy from Neutral at Guggenheim
08/22/19 Guggenheim
HMS Holdings downgraded to Neutral after 'impressive run' at Guggenheim
Hot Stocks
HMS Holdings sees FY20 CapEx approximately $30M-$35M » 06:10
02/21/20
02/21
06:10
02/21/20
06:10
HMSY

HMS Holdings

$27.47 /

-0.68 (-2.42%)

Sees FY20 effective tax…

Sees FY20 effective tax rate 28%-30%.

ShowHide Related Items >><<
HMSY HMS Holdings
$27.47 /

-0.68 (-2.42%)

01/08/20 Credit Suisse
HMS Holdings reinstated with an Outperform at Credit Suisse
11/22/19 Guggenheim
Guggenheim upgrades HMS Holdings to Buy on 'compelling' risk/reward
11/22/19 Guggenheim
HMS Holdings upgraded to Buy from Neutral at Guggenheim
08/22/19 Guggenheim
HMS Holdings downgraded to Neutral after 'impressive run' at Guggenheim
Earnings
HMS Holdings sees FY20 revenue $705M-$715M, consensus $701.56M » 06:03
02/21/20
02/21
06:03
02/21/20
06:03
HMSY

HMS Holdings

$27.47 /

-0.68 (-2.42%)

Sees FY20 adjusted EBITDA…

Sees FY20 adjusted EBITDA $185M-$192M.

ShowHide Related Items >><<
HMSY HMS Holdings
$27.47 /

-0.68 (-2.42%)

01/08/20 Credit Suisse
HMS Holdings reinstated with an Outperform at Credit Suisse
11/22/19 Guggenheim
Guggenheim upgrades HMS Holdings to Buy on 'compelling' risk/reward
11/22/19 Guggenheim
HMS Holdings upgraded to Buy from Neutral at Guggenheim
08/22/19 Guggenheim
HMS Holdings downgraded to Neutral after 'impressive run' at Guggenheim
Earnings
HMS Holdings reports Q4 adjusted EPS 27c, consensus 31c » 06:02
02/21/20
02/21
06:02
02/21/20
06:02
HMSY

HMS Holdings

$27.47 /

-0.68 (-2.42%)

Reports Q4 revenue…

Reports Q4 revenue $163.4M, consensus $170.79M.

ShowHide Related Items >><<
HMSY HMS Holdings
$27.47 /

-0.68 (-2.42%)

01/08/20 Credit Suisse
HMS Holdings reinstated with an Outperform at Credit Suisse
11/22/19 Guggenheim
Guggenheim upgrades HMS Holdings to Buy on 'compelling' risk/reward
11/22/19 Guggenheim
HMS Holdings upgraded to Buy from Neutral at Guggenheim
08/22/19 Guggenheim
HMS Holdings downgraded to Neutral after 'impressive run' at Guggenheim
Conference/Events
JPMorgan to hold a conference » 10:25
01/16/20
01/16
10:25
01/16/20
10:25
ELGX

Endologix

$1.86 /

+0.01 (+0.54%)

, FPRX

Five Prime

$5.00 /

+0.04 (+0.81%)

, HMSY

HMS Holdings

$29.87 /

+0.64 (+2.19%)

, IDRA

Idera Pharmaceuticals

$1.91 /

+0.035 (+1.87%)

, LXRX

Lexicon

$4.37 /

+0.115 (+2.70%)

, RIGL

Rigel Pharmaceuticals

$3.00 /

+0.27 (+9.89%)

, TRXC

TransEnterix

$1.59 /

-0.03 (-1.85%)

, NVDA

Nvidia

$248.87 /

+3.35 (+1.36%)

, JNCE

Jounce Therapeutics

$7.96 /

+0.275 (+3.58%)

, GRTS

Gritstone Oncology

$11.94 /

+0.6 (+5.29%)

, STRO

Sutro Biopharma

$11.83 /

+ (+0.00%)

, ZIOP

Ziopharm

$5.04 /

+0.09 (+1.82%)

, IMGN

ImmunoGen

$4.93 /

-0.02 (-0.40%)

, ATRC

AtriCure

$36.13 /

+0.79 (+2.24%)

, ACOR

Acorda Therapeutics

$2.14 /

+0.015 (+0.71%)

, ARNA

Arena Pharmaceuticals

$46.25 /

+1.1 (+2.44%)

, KURA

Kura Oncology

$13.02 /

+0.15 (+1.17%)

, NXTC

NextCure

$54.34 /

+0.95 (+1.78%)

, VEEV

Veeva

$146.52 /

+2 (+1.38%)

, RVNC

Revance

$22.84 /

-0.06 (-0.26%)

, ISEE

Iveric bio

$6.81 /

+ (+0.00%)

, INSP

Inspire Medical

$82.38 /

+1.13 (+1.39%)

, CLSD

Clearside Biomedical

$2.45 /

+0.07 (+2.94%)

, MSON

Misonix

$18.93 /

+ (+0.00%)

, KRTX

Karuna Therapeutics

$85.65 /

+0.37 (+0.43%)

38th Annual Healthcare…

38th Annual Healthcare Conference is being held in San Francisco on January 13-16 with webcasted company presentations to begin on January 16 at 10:30 am; not all company presentations may be webcasted. Webcast Link

ShowHide Related Items >><<
ELGX Endologix
$1.86 /

+0.01 (+0.54%)

10/28/19 Piper Sandler
FDA notice another negative data point for Endologix, says Piper Jaffray
05/02/19 Piper Sandler
Endologix earnings call brighter but risks remain, says Piper Jaffray
04/01/19 Piper Sandler
Piper Jaffray sees Endologix's updates as 'positive'
FPRX Five Prime
$5.00 /

+0.04 (+0.81%)

11/20/19 Guggenheim
Five Prime assumed with a Neutral at Guggenheim
10/01/19 Guggenheim
Five Prime cut to Neutral after ESMO readout, management exits at Guggenheim
09/30/19 Guggenheim
Five Prime downgraded to Neutral from Buy at Guggenheim
06/03/19
Five Prime downgraded to Market Perform following ASCO data at Wells Fargo
HMSY HMS Holdings
$29.87 /

+0.64 (+2.19%)

01/08/20 Credit Suisse
HMS Holdings reinstated with an Outperform at Credit Suisse
11/22/19 Guggenheim
Guggenheim upgrades HMS Holdings to Buy on 'compelling' risk/reward
11/22/19 Guggenheim
HMS Holdings upgraded to Buy from Neutral at Guggenheim
08/22/19 Guggenheim
HMS Holdings downgraded to Neutral after 'impressive run' at Guggenheim
IDRA Idera Pharmaceuticals
$1.91 /

+0.035 (+1.87%)

03/08/19 H.C. Wainwright
Idera Pharmaceuticals price target lowered to $14 from $18 at H.C. Wainwright
03/07/19 Wedbush
Idera Pharmaceuticals price target lowered to $7 from $16 at Wedbush
LXRX Lexicon
$4.37 /

+0.115 (+2.70%)

12/20/19 Stifel
Stifel says Lexicon 'missed opportunity' with sotagliflozin data
12/11/19 Gabelli
Lexicon downgraded to Hold on valuation at Gabelli
12/11/19 Gabelli
Lexicon downgraded to Hold from Buy at Gabelli
11/08/19 Citi
Lexicon downgraded to Neutral from Buy at Citi
RIGL Rigel Pharmaceuticals
$3.00 /

+0.27 (+9.89%)

01/16/20 H.C. Wainwright
Rigel launch of Tavalisse remains encouraging, says H.C. Wainwright
01/13/20 Piper Sandler
Rigel still one of the most under-appreciated stories in sector, says Piper
11/15/19
Fly Intel: Top five analyst initiations
11/15/19 Cantor Fitzgerald
Rigel Pharmaceuticals assumed with an Overweight at Cantor Fitzgerald
TRXC TransEnterix
$1.59 /

-0.03 (-1.85%)

08/08/19 RBC Capital
TransEnterix downgraded to Sector Perform from Outperform at RBC Capital
07/11/19 Piper Sandler
TransEnterix asset sale doesn't change thesis, says Piper Jaffray
05/22/19
Fly Intel: Top five analyst initiations
05/22/19 Piper Sandler
TransEnterix initiated with a Neutral at Piper Jaffray
NVDA Nvidia
$248.87 /

+3.35 (+1.36%)

01/15/20 Piper Sandler
Piper sees 2020 as 'major recovery year' for Semiconductors
01/13/20
Fly Intel: Top five analyst upgrades
01/13/20 Craig-Hallum
Nvidia price target raised to $300 from $255 at Craig-Hallum
01/13/20 Needham
Nvidia upgraded to Hold from Underperform at Needham
JNCE Jounce Therapeutics
$7.96 /

+0.275 (+3.58%)

GRTS Gritstone Oncology
$11.94 /

+0.6 (+5.29%)

07/26/19
Fly Intel: Top five analyst initiations
07/25/19 Baird
Gritstone Oncology initiated with an Outperform at Baird
03/27/19 Berenberg
Gritstone Oncology initiated with a Buy at Berenberg
03/14/19 Raymond James
Gritstone Oncology initiated with an Outperform at Raymond James
STRO Sutro Biopharma
$11.83 /

+ (+0.00%)

01/13/20 SunTrust
Sutro Biopharma initiated with a Buy at SunTrust
10/07/19
Fly Intel: Top five analyst initiations
10/07/19 BTIG
Sutro Biopharma initiated with a Buy at BTIG
09/05/19 JMP Securities
Sutro Biopharma resumed with an Outperform at JMP Securities
ZIOP Ziopharm
$5.04 /

+0.09 (+1.82%)

08/23/19
Fly Intel: Top five analyst initiations
08/22/19 Raymond James
Ziopharm resumed with an Outperform at Raymond James
04/04/19 Lake Street
Ziopharm initiated with a Buy at Lake Street
04/01/19 Laidlaw
Ziopharm initiated with a Buy at Laidlaw
IMGN ImmunoGen
$4.93 /

-0.02 (-0.40%)

12/17/19 H.C. Wainwright
ImmunoGen price target hiked to $9 after 'compelling' advance at H.C. Wainwright
09/29/19 Piper Sandler
Biomarker screening reason for ImmunoGen FORWARD I failure, says Piper Jaffray
05/15/19 H.C. Wainwright
H.C. Wainwright says 'wrong again' about ImmunoGen, lowers price target to $4
05/15/19 Guggenheim
ImmunoGen downgraded to Neutral from Buy at Guggenheim
ATRC AtriCure
$36.13 /

+0.79 (+2.24%)

01/13/20 Piper Sandler
AtriCure 2020 outlook likely to be conservative, says Piper Sandler
01/07/20 Piper Sandler
Piper Sandler remains bullish on AtriCure as aMAZE enrollment completes
12/02/19 Piper Sandler
Piper sees 'significant valuation creation on the horizon' for AtriCure
09/20/19 Piper Sandler
AtriCure one of the most compelling names in cardiology, says Piper Jaffray
ACOR Acorda Therapeutics
$2.14 /

+0.015 (+0.71%)

10/24/19 JPMorgan
JPMorgan downgrades Acorda to Underweight on disappointing Inbrija launch
10/24/19 JPMorgan
Acorda Therapeutics downgraded to Underweight from Neutral at JPMorgan
09/30/19 BofA
Adamas Pharmaceuticals downgraded to Underperform from Neutral at BofA/Merrill
08/14/19 H.C. Wainwright
Acorda Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
ARNA Arena Pharmaceuticals
$46.25 /

+1.1 (+2.44%)

01/08/20 JMP Securities
Arena Pharmaceuticals has right management team in place, says JMP Securities
11/13/19 BofA
Arena Pharmaceuticals initiated with a Neutral at BofA/Merrill
04/03/19 Credit Suisse
Arena Pharmaceuticals price target raised to $77 from $63 at Credit Suisse
01/29/19
Fly Intel: Top five analyst initiations
KURA Kura Oncology
$13.02 /

+0.15 (+1.17%)

11/07/19 Wedbush
Wedbush still views Kura Oncology as a top pick
10/29/19 Piper Sandler
Kura pivotal trial 'highly likely to succeed,' says Piper Jaffray
09/05/19 JMP Securities
Kura Oncology resumed with an Outperform at JMP Securities
07/18/19 Deutsche Bank
Kura Oncology initiated with a Buy at Deutsche Bank
NXTC NextCure
$54.34 /

+0.95 (+1.78%)

01/13/20 Piper Sandler
Partnership termination not a negative for NextCure N318, says Piper Sandler
01/13/20 SunTrust
NextCure initiated with a Buy at SunTrust
01/06/20 Piper Sandler
NextCure named a top pick for 2020 at Piper Sandler
12/05/19 Needham
NextCure initiated with a Buy at Needham
VEEV Veeva
$146.52 /

+2 (+1.38%)

01/13/20 Morgan Stanley
Veeva upgraded to Overweight following underperformance at Morgan Stanley
01/13/20 Morgan Stanley
Veeva upgraded to Overweight from Equal Weight at Morgan Stanley
01/07/20 Deutsche Bank
Veeva price target lowered to $150 from $160 at Deutsche Bank
12/26/19 Stifel
Stifel sees path to $230 for Iqvia shares after 'significant' AstraZeneca win
RVNC Revance
$22.84 /

-0.06 (-0.26%)

01/10/20 William Blair
Revance deal positions it as 'emerging aesthetics leader,' says William Blair
12/01/19 Goldman Sachs
Revance initiated with a Buy at Goldman Sachs
10/30/19 Wells Fargo
Wells Fargo upgrades Revance to Outperform, boosts target to $20
10/30/19 Wells Fargo
Revance upgraded to Outperform from Market Perform at Wells Fargo
ISEE Iveric bio
$6.81 /

+ (+0.00%)

01/07/20
Fly Intel: Top five analyst initiations
01/06/20 Wedbush
Wedbush starts Iveric bio with Outperform rating, $13 price target
01/06/20 Wedbush
IVERIC bio initiated with an Outperform at Wedbush
INSP Inspire Medical
$82.38 /

+1.13 (+1.39%)

01/16/20 Wells Fargo
Inspire Medical price target raised to $90 from $70 at Wells Fargo
11/06/19 Berenberg
Inspire Medical upgraded to Hold from Sell at Berenberg
09/27/19 Dougherty
Inspire Medical received positive draft LCDs from two more MACs, says Dougherty
07/08/19 BofA
Inspire Medical price target raised to $75 from $65 at BofA/Merrill
CLSD Clearside Biomedical
$2.45 /

+0.07 (+2.94%)

12/17/19 JMP Securities
FDA to accept RVO clinial use data from Clearside, says JMP Securities
10/14/19 Roth Capital
Ophthalmic therapies 'could go from 0 to 100 real quick,' says Roth Capital
08/22/19 JMP Securities
Clearside Biomedical price target lowered to $3 from $4 at JMP Securities
08/13/19 Laidlaw
Laidlaw downgrades Clearside Biomedical to Hold after Xipere partnering
MSON Misonix
$18.93 /

+ (+0.00%)

12/31/19 Craig-Hallum
Misonix's amended credit line removes capital needs questions, says Craig-Hallum
08/15/19 Canaccord
Misonix price target raised to $30 from $24 at Canaccord
06/12/19
Fly Intel: Top five analyst initiations
06/12/19 BTIG
Misonix initiated with a Buy at BTIG
KRTX Karuna Therapeutics
$85.65 /

+0.37 (+0.43%)

01/14/20 William Blair
Karuna Therapeutics' KarXT surpasses expectations, says William Blair
01/09/20 JMP Securities
Karuna Therapeutics initiated with an Outperform at JMP Securities
12/19/19 Stifel
Karuna Therapeutics initiated with a Buy at Stifel
12/12/19 William Blair
Karuna Therapeutics initiated with an Outperform at William Blair

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.